1083 patents
Page 5 of 55
Utility
Long-term Medicament Storage Apparatus and Methods
19 Oct 23
An apparatus for storing a medicament delivery device, the apparatus comprising: a container defining a storage cavity having an opening, the storage cavity configured to receive a syringe pre-filled with medicament; an absorbent disposed in the cavity, the absorbent at least partially hydrated with a liquid solution; and a seal member at least selectively connected with the cavity to form a seal that is at least substantially gas impermeable.
Alan Dominguez, Nicholas J. Clark
Filed: 3 Sep 21
Utility
Materials and Methods to Reduce Protein Aggregation
19 Oct 23
Provided herein are methods of treating a neoplastic disease in a subject.
Arnold J. MCAULEY, Michael SCHNEIDER
Filed: 10 Sep 21
Utility
Chimeric Receptors and Methods of Use Thereof
19 Oct 23
Antigen binding molecules, chimeric receptors, and engineered immune cells are disclosed in accordance with the invention.
Jed WILTZIUS, Ruben ALVAREZ RODRIGUEZ, Alice BAKKER, Lawren WU, Tara ARVEDSON
Filed: 3 Mar 23
Utility
Process control systems and methods for use with filters and filtration processes
17 Oct 23
Systems and methods used to control tangential flow filtration are provided, including control systems and methods for use with connected systems with upstream processing units, such as chromatography processing units, in fluid communication with a tangential flow filtration processing unit.
Eva Gefroh, Randolph W. Schweickart, Krista Petty, Gregory Frank, Christine Salstrom Terpsma, Arthur C. Hewig, III, Joseph Edward Shultz
Filed: 29 Jun 21
Utility
Heteroaryl-biphenyl Amides for the Treatment of PD-L1 Diseases
12 Oct 23
Pingchen FAN, Christopher W. LANGE, Rebecca M. LUI, Darren J. McMURTRIE, Ryan J. SCAMP, Ju YANG, Yibin ZENG, Penglie ZHANG
Filed: 12 Jun 23
Utility
Immunogens Derived from SARS-COV2 Spike Protein
12 Oct 23
The present invention relates to severe acute respiratory syndrome coronavirus 2 (“SARS-CoV2”) immunogens useful for the generation of therapeutic antibodies and vaccine development.
Fernando GARCES, Zhulun WANG, Timothy RILEY
Filed: 22 Jul 21
Utility
Overexpression of Insulin-like Growth Factor Receptor Mutants to Modulate Igf Supplementation
12 Oct 23
Methods of mammalian cell culture for expressing a recombinant protein of interest are provided.
Kristine Marie DARIS, Fides Dwinan LAY
Filed: 1 Nov 21
Utility
Antigen Binding Proteins with Non-canonical Disulfide In Fab Region
12 Oct 23
The ability to generate a single antibody-based construct that can recognize multiple targets simultaneously, is paramount to advance many therapeutics candidates to clinic.
Fernando GARCES, Zhulun WANG
Filed: 19 Aug 21
Utility
Bisamide sarcomere activating compounds and uses thereof
10 Oct 23
Luke Ashcraft, Alessandro Boezio, John Butler, Aroop Chandra, Chihyuan Chuang, Scott E. Collibee, Mikkel Debenedetto, Vincent Dimassa, Russell Graceffa, Justin Malinowski, David Moebius, Bradley P. Morgan, Joshua Payette, Antonio Romero, David St. Jean, Jr., Richard Vargas, John Yeoman, Hanmo Zhang, Alan Cheng, Felix Gonzalez Lopez De Turiso, Michael Garrett Johnson
Filed: 15 Feb 22
Design
Autoinjector with removable cap
10 Oct 23
Margaux Frances Boyaval, Sigrid Moeslinger, Masamichi Udagawa
Filed: 13 May 21
Utility
PACAP antibodies and uses thereof
10 Oct 23
The present invention relates to monoclonal antibodies that specifically bind to human pituitary adenylate cyclase activating polypeptide (PACAP) and pharmaceutical compositions comprising such antibodies.
Agnes E. Hamburger, Cen Xu, Hong Sun, Yuan D. Shih, Dohan Weeraratne
Filed: 24 Sep 20
Utility
Method of treating C3 glomerulopathy
10 Oct 23
Methods of treating a human suffering from or susceptible to C3 glomerulopathy comprising administering to the human an effective amount of a C5aR antagonist are provided.
Petrus Bekker
Filed: 14 Feb 22
Utility
Method of Making Lyophilized Protein Formulations
5 Oct 23
Disclosed herein are methods of preparing lyophilized formulations comprising a protein, such as an antibody or a bispecific antibody construct, that exhibits improved storage stability.
Arnold McAuley, Michael J. Treuheit, Twinkle R. Christian, Bharadwaj Jagannathan
Filed: 14 Sep 21
Utility
MCL-1 Inhibitor Formulations
5 Oct 23
Provided herein are solid dispersions comprising AMG 397, methods of preparing the solid dispersion, and pharmaceutical formulations comprising AMG 397.
JAMES E. HUCKLE, MARKIAN M. STEC, TIAN WU, DARREN L. REID, FERNANDO A. ALVAREZ-NUNEZ, SEAN P. BROWN
Filed: 24 Aug 21
Utility
Methods and Compositions for the Treatment of Celiac Disease, Non-Celiac Gluten Sensitivity, and Refractory Celiac Disease
5 Oct 23
Methods and pharmaceutical compositions are provided herein for the treatment of inflammatory disorders, in particular celiac disease, refractory celiac disease and non-celiac gluten sensitivity.
Francisco Leon, Wayne H. Tsuji
Filed: 24 Mar 23
Utility
Monoclonal Antibodies to Chemically-modified Nucleic Acids and Uses Thereof
5 Oct 23
The present invention relates to monoclonal antibodies that specifically bind to chemically-modified nucleic acid molecules, including pan-specific antibodies that bind to chemically-modified nucleic acid molecules independent of nucleotide sequence.
Brian CHAN, Weihsu Claire CHEN, Sara HUMPHREYS, Agnieszka KIELCZEWSKA, Mai THAYER
Filed: 22 Mar 21
Utility
Salt Forms and Solvates of MCI-1 Antagonists
5 Oct 23
Henry Morrison, Jason S. Tedrow, Stephan D. Parent, Courtney Johnson, Travis Houston, Melanie Bevill
Filed: 5 Apr 23
Utility
Antibody Constructs for DLL3 and CD3
5 Oct 23
The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human DLL3 on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell.
Tobias Raum, Claudia Blümel, Christoph Dahlhoff, Patrick Hoffmann, Peter Kufer, Ralf Lutterbüse, Elisabeth Nahrwold, Jochen Pendzialek
Filed: 21 Dec 22
Utility
Syringe de-capper device
3 Oct 23
A syringe de-capper including a base having a lower surface and an upper surface opposite the lower surface.
Jeffrey C. Yeary
Filed: 3 Mar 22
Utility
6-5 fused rings as C5a inhibitors
3 Oct 23
Pingchen Fan, Christopher W. Lange, Rebecca M. Lui, Viengkham Malathong, Venkat Reddy Mali, Sreenivas Punna, Rajinder Singh, Hiroko Tanaka, Yibin Zeng, Penglie Zhang
Filed: 3 May 22